Silenceworks latest edition

Posted today:

Dear ,

I’m pleased to attach the latest edition of Silenceworks. As you can see, April to July has been a very significant period for Benitec:

• The first patient was dosed in Benitec's TT-034 Hepatitis C clinical trial
• Maxim and Shaw both initiated coverage of Benitec with ‘buy’ recommendations
• Calimmune gained approval to commence dosing the second cohort of patients in their HIV clinical trial

and much more. To read Silenceworks 8, please use this link. Call me if you’d care to discuss it or our programs.

Regards,
Carl Stubbings| Chief Business Officer
Benitec Biopharma Limited | F6A / 1-15 Barr Street | Balmain NSW 2041 Australia
ABN: 64068943662
t:   (+61 2) 9555 6986 |m:   (+61) 423666374|
e:[email protected] | w: www.benitec.com |Skype: carl-stubbings